The combination of bevacizumab plus trabectedin (BT) shows promising clinical activity with limited toxicity in the treatment of women with partially platinum-sensitive ovarian cancer, according to the results of a phase II study. A regimen consisting of BT plus carboplatin also has good activity although with relatively increased toxicity.
A personalized approach in the dosing of subcutaneous tocilizumab (TCZ) injections according to body weight appears to be effective in improving outcomes of clinical disease activity in patients with rheumatoid arthritis (RA), suggests a study.
Use of sodium bicarbonate in the treatment of patients with chronic kidney disease stages 3 and 4 leads to an increase in serum bicarbonate and decrease in potassium levels, but with little to no effect on muscle function or bone mineral density when compared with placebo, according to the results of a trial.
The selective bradykinin B2 receptor antagonist icatibant proves to be effective and safe for managing acute attacks in Japanese patients with hereditary angioedema, according to the results of a small phase III open-label trial.
Despite a relatively low rate of relapse of intolerance among patients taking pravastatin or fluvastatin, many of them have eventually discontinued or switched to other medication, reveals a study. Relapse is independently predicted by chronic kidney disease and history of creatine kinase elevation.
Low heart rate (HR) in patients with heart failure (HF) and atrial fibrillation (AF) receiving treatment with beta-blockers contributes to an increase in the risk of cardiovascular events, suggesting that a low HR may blunt the beneficial effects of the said drugs, a study has found.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Using a humanized antidisialoganglioside mAb (hu14.18K322A) in combination with induction chemotherapy appears to yield favourable outcomes in children with high-risk neuroblastoma, including induction of an early response, improvement of Curie scores (CSs) and a 2-year event-free survival (EFS), according to the results of a phase II trial.
Aspirin use does not appear to result in progression of age-related macular degeneration (AMD) or its subtypes in either the Age-Related Eye Disease Study (AREDS) or AREDS2, a study has shown. Thus, there is no need to avoid aspirin use when it is medically indicated in AMD patients.
The combination of glecaprevir and pibrentasvir (G/P) may be a viable option for patients with genotype 1 hepatitis C virus (HCV) infection who had failed prior treatment with sofosbuvir and a nonstructural protein inhibitor, a new study has shown.
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]